Study Shows Guardant360® Liquid Biopsy Test Helps Guide Treatment for Patients with HER2-Driven Metastatic Colorectal Cancer
Guardant Health, Inc. (GH)
Last guardant health, inc. earnings: 2/24 04:03 pm
Check Earnings Report
Company Research
Source: Business Wire
The study, published in Nature Medicine, demonstrates that the Guardant360® test helps identify patients who may benefit from treatment and can identify alterations that predict resistance REDWOOD CITY, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that a study published in Nature Medicine reinforces the benefits of using the Guardant360® liquid biopsy test to help guide treatment decisions for patients with HER2-driven metastatic colorectal cancer (mCRC). Led by the National Cancer Center Hospital East (NCCHE) in Japan, the study demonstrates that the Guardant360 test can select patients for HER2-directed therapy, identify which patients are responding to treatment, as well as identify genetic alterations that predict resistance.The Phase 2 TRastuzumab combIned with pertuzUMab for Patients with Her2-positive mCRC (TRIUMPH) study evaluated the efficacy of targeted therapy pertuzumab plus trastuzumab in patients wi
Show less
Read more
Impact Snapshot
Event Time:
GH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GH alerts
High impacting Guardant Health, Inc. news events
Weekly update
A roundup of the hottest topics
GH
News
- Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics [Yahoo! Finance]Yahoo! Finance
- Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue Guidance [Yahoo! Finance]Yahoo! Finance
- Guardant Health Reports First Quarter 2024 Financial Results and Increases 2024 Revenue GuidanceBusiness Wire
- U.S. Liquid Biopsy Market to Attain Valuation of USD 12,004.9 Million By 2032: Astute Analytica [Yahoo! Finance]Yahoo! Finance
GH
Earnings
- 5/9/24 - Beat
GH
Sec Filings
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 5/6/24 - Form 4
- GH's page on the SEC website